Drug intelligence / Profile preview

ado-trastuzumab emtansine + bintrafusp alfa

Development stage: Unknown
Lead developer: Genentech
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A combination therapy consisting of ado-trastuzumab emtansine (T-DM1, Kadcyla) and bintrafusp alfa. This combination pairs an antibody-drug conjugate targeting HER2-positive breast cancer cells with a bifunctional fusion protein that simultaneously blocks PD-L1 and TGF-β pathways. The combination is being investigated for its potential to enhance anti-tumor activity through multiple mechanisms including direct cytotoxicity and immune modulation.

Brand names: Kadcyla + bintrafusp alfa

Targets

CD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)MicrotubuleERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on ado-trastuzumab emtansine + bintrafusp alfa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ado-trastuzumab emtansine + bintrafusp alfa.

Explore the full profile